RegulationConditional marketing approval (China), Special Review Project (China), Orphan Drug (United States), Breakthrough Therapy (China), Priority Review (China)

Structure/Sequence

Molecular FormulaC28H37FN6O5S

InChIKeyNVWKNQGHVMMAJW-UHFFFAOYSA-N

CAS Registry1702816-75-8

Clinical Trials associated with Linperlisib

NCT06793956

/ RecruitingPhase 1IIT

Open-Label, Phase Ib Study of Sintilimab and Linperlisib Combination Treatment in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (NKTCL)

This is an open-label, phase Ib study evaluating the combination treatment of sintilimab and linperlisib in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (NKTCL).

Start Date21 Feb 2025

Sponsor / Collaborator

Sun Yat-Sen University

NCT06799676

/ Not yet recruitingPhase 1/2IIT

A Single-Arm, Multicenter, Open-Label Phase Ib/II Clinical Study on the Application of Linperlisib Plus the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma

This study aims to evaluate the safety and efficacy of Linperlisib combined with the VRD regimen in the treatment of newly diagnosed patients with multiple myeloma. The study is divided into a Phase Ib dose exploration phase and a Phase II expansion phase.The Phase Ib dose exploration phase primarily aims to determine the recommended Phase II dose (RP2D) of Linperlisib based on dose-limiting toxicity (DLT). The Phase II expansion phase involves induction therapy using at least four cycles of Linperlisib at RP2D in combination with the VRD regimen. After completing four cycles of induction therapy, patients eligible for autologous hematopoietic stem cell transplantation (ASCT) will undergo the procedure. For patients whose therapeutic evaluation results in PD (progressive disease) or SD (stable disease), alternative treatment regimens will be considered based on their condition. After successful transplantation, 2-4 cycles of the original induction regimen will be used for consolidation therapy.The primary objective is to evaluate the proportion of patients achieving a very good partial response (VGPR) after four cycles of induction therapy with the Linperlisib combined VRD regimen.

Start Date01 Feb 2025

Sponsor / Collaborator

Zhongnan hospital of wuhan university

NCT06712173

/ Not yet recruitingPhase 1IIT

A Single Arm, Open Label, Single-center Dose-exploratory Clinical Study of Linperlisib in Combination With EZH2 Inhibitor SHR2554 in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

This is a Phase I, multicenter, non-randomized, open-label, dose-exploratory clinical study to evaluate the safety and tolerability of linperlisib combined with SHR2554 in the treatment of R/R PTCL, and to preliminary observe the antitumor efficacy of the combination of the two drugs.

Start Date01 Dec 2024

Sponsor / Collaborator

Hematology Hospital of Chinese Academy of Medical Sciences

100 Clinical Results associated with Linperlisib

100 Translational Medicine associated with Linperlisib

100 Patents (Medical) associated with Linperlisib

Literatures (Medical) associated with Linperlisib

01 Feb 2025·International Journal of Clinical Oncology

Phase Ib study of the oral PI3Kδ inhibitor linperlisib in patients with advanced solid tumors

Article

Author: Shentu, Jiangzhong ; Xu, Nong ; Mou, Haibo ; Zhang, Jun ; Li, Jin ; Xue, Junli ; Xu, Zusheng ; Liu, Tianshu ; Bao, Hanying ; Feng, Yi ; Yin, Yongmei ; Xu, Zuhong ; Huang, Jianjin

AbstractBackgroundPatients with advanced solid tumors have a suboptimal prognosis. This study investigated the safety and feasibility of linperlisib, a selective phosphatidylinositol 3-kinase delta isoform (PI3Kδ) inhibitor, for treating patients with advanced solid tumors.MethodsIn this phase Ib, single-arm, open-label, multi-center clinical trial, patients with histologically confirmed advanced solid tumors from eight centers in China were enrolled to receive oral linperlisib (80 mg/day). The primary endpoint was safety.ResultsBetween August 2019 and June 2022, 94 patients were enrolled in the trial and received the study treatment. The most common (≥ 20%) treatment emergent adverse events (TEAEs) of all grades irrespective of causality were increased aspartate aminotransferase (AST) (26.6%), proteinuria (26.6%), decreased appetite (25.5%), increased alanine aminotransferase (ALT) (22.3%), weight loss (21.3%), and anemia (21.3%). The most common grade ≥ 3 TEAEs were diarrhea (4.3%), increased AST (3.2%), increased ALT (3.2%), neutropenia (3.2%), anemia (3.2%), increased blood alkaline phosphatase (3.2%). The objective response rate (ORR) was 1.1% (95% confidence interval [CI] 0.0–5.8), and the disease control rate (DCR) was 37.2% (95% CI 27.5–47.8). As of the data cutoff, the median follow-up time was 4.2 months (95% CI 2.8–6.9). The median progression-free survival (PFS) was 1.85 months (95% CI 1.79–1.88). The median overall survival (OS) was not reached.ConclusionLinperlisib showed an acceptable safety profile and preliminary clinical benefit in patients with a range of advanced solid tumors. Further studies of linperlisib safety and efficacy are warranted.

15 Oct 2024·Clinical Cancer Research

A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma

Article

Author: Li, Fei ; Xu, Zusheng ; Huang, Wenyang ; Qiu, Lugui ; Bao, Hanying ; Wu, Tao ; Jin, Jie ; Yang, Haiyan ; Wang, Zhen ; Cen, Hong ; Li, Zhiming ; Xu, Xiaohong ; Zhou, Keshu

AbstractPurpose:Relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) is an aggressive and heterogeneous hematologic malignancy with high unmet need. Previously, PI3K inhibitors were shown to be efficacious in B- and T-cell lymphomas, but as a drug class, these agents have frequently been observed to have tolerability limitations. Next-generation agents that improve the tolerability while maintaining efficacy are desirable.Patients and Methods:A phase Ib clinical study was conducted with the oral PI3K-delta isoform-selective small-molecule inhibitor, linperlisib, in patients with r/r PTCL, and the clinical benefit was explored by the evaluation of safety and efficacy.Results:In this clinical study, 43 patients with r/r PTCL in China were treated with continuous dosing of 80-mg linperlisib once a day. Treatment-related adverse events (AE) were manageable. The most frequently reported grade 3 AE were neutropenia (21%), pneumonia (11.6%), and hypertriglyceridemia (7%). All other AE were either absent or reported in <5% of the patients. Linperlisib treatment for these patients with r/r PTCL, consisting of the major PTCL subtypes, was observed to have a 60.5% overall response rate with 35% complete responses and led to a median duration of response of 11.1 months, median progression-free survival of 11.8 months, and a median overall survival of >38 months (not reached).Conclusions:With the very promising clinical activity against r/r PTCL, the results of this study support the further investigation of linperlisib for the treatment of r/r PTCL.

01 Jul 2024·American Journal of Hematology

Patients with acquired pure red cell aplasia respond to PI3Kδ inhibitor rapidly

Letter

Author: Tao, Yuan ; Li, Xiaoxia ; Li, Chunhong ; Sun, Qi ; Jiang, Bo ; Sun, Mingyuan ; Zheng, Weiwei ; Qi, Junyuan ; Wang, Zhenzhen ; Song, Lin

Pure red cell aplasia (PRCA) is a rare disease for which large controlled trials are challenging and as such recommendations are mostly based on retrospective studies or case accumulations.Cyclosporine A (CsA) provides the most effective treatment for PRCA with an overall response rate of 65% - 87%, leaving approx. one-third of patients in need of an alternative agent.Case 1: A 48-yr-old female diagnosed with PRCA associated with T-LGLL and monoclonal gammopathy of undetermined significance (MGUS) started on Linperlisib 80 mg daily 12 mo ago after failing to respond to CsA along with prednisone taper.Case 2: A 63-yr-old female was diagnosed with T-LGLL associated PRCA 5 years ago, her Hb maintained normal for 4 years with CsA and steroid taper, and linperlisib 80 mg per day was orally administered due to relapsed anemia and Hb level was elevated from 6.3 to 7.7 g/dL in 1 wk.Case 3: A 79-yr-old man was confirmed to have T-LGLL associated PRCA 5 mo ago, he was intolerant to first-line therapy composed of CsA and methylprednisolone due to severe transaminase elevation, the attempt of Linperlisib 80 mg daily resulted in a progressive and rapid rise of Hb level, peaking at 11.1 g/dL, effectively eliminating the requirement for transfusions.Case 4: A 54-yr-old male with anemia was diagnosed with PRCA associated with MGUS 1 yr ago. Initial therapy composed of stanozolol, followed by CsA and prednisone did not decrease transfusion requirements and led to the therapy of Linperlisib 80 mg daily.

News (Medical) associated with Linperlisib

11 Dec 2023

·www.prnewswire.com

Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib in relapsed or refractory peripheral T-cell lymphoma in an oral session at the American Society of Hematology 2023 Annual Meeting

Linperlisib achieved Overall Response Rate of 48% with 30% being Complete Response and manageable safety profile in the r/r PTCL phase 2 study SHANGHAI and SAN FRANCISCO, Dec. 11, 2023 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (" Yingli Pharma"), a biopharmaceutical company focused on developing oral therapies for cancer and metabolic diseases, today announced the pivotal Phase 2 clinical trial results of the investigation of linperlisib in the treatment of patients with relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL). Linperlisib is a phosphoinositide 3-kinase delta (PI3Kδ) oral inhibitor, approved in China for treatment of patients with r/r follicular lymphoma after systemic therapy. "There is a vital need for new therapies to treat highly aggressive cancers such as r/r PTCL where there are very limited treatment options." said Dr. Jun Zhu, Professor, Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China, who was the leading investigator for this pivotal clinical trial. "In addition to the promising efficacy and well manageable safety of linperlisib in r/r PTCL, it is noteworthy that a high proportion of the treated patients were shown to have a complete response, and responses have been seen in all the major PTCL subtypes." "Our approach is to develop novel oral agents that will allow patients to safely administer at home," said Michael Hui, CEO of Yingli Pharma, "We are delighted that the encouraging results of this study support the use of linperlisib in this hard-to-treat disease and are excited to continue developing linperlisib in more indications. The company has applied for linperlisib marketing approval in r/r PTCL in China based on these pivotal study findings." Mr. Hui added, "We look forward to the results of an ongoing open-label multi-center Phase 2 study in the U.S. and Italy in r/r PTCL and r/r CTCL." Safe and effective treatment of r/r PTCL patients The pivotal r/r PTCL Phase 2 clinical trial enrolled 98 patients (pts) from May 2021 to October 2022 at 25 clinical sites in China. The pts had a median of two lines of prior systemic therapies. Sixty-four pts (73%) had refractory disease, 59 pts (67%) had relapsed disease, and 35 pts (40%) had both relapsed and refractory diseases. All patients received linperlisib at 80 mg QD, the RP2D for the drug, with a minimum of 6 months follow-up. The linperlisib-treated patients (Full Analysis Set N = 88) evaluated by Lugano criteria, had a 48% overall response rate, including 30% complete responses and 18% partial responses, as well as a 68% disease control rate. The median Duration of Response was not reached although the 6-month DOR rate was 75%. The median PFS was 5.5 months (95% CI, 3.5, 15.6) and the median OS was 14.2 months (95%CI, 7.9, not reached). Responses were observed across PTCL subtypes. Linperlisib was well tolerated with a differentiated and manageable safety profile, specifically having very low levels of immune-mediated toxicities. In the linperlisib-treated patient safety dataset (N=98) for the pivotal study, the most common hematologic treatment related adverse events (TRAEs) of Grade≥3 were neutropenia (32%), leukocytopenia (10%), Anemia (6%), Thrombocytopenia (5%), and Lymphocytopenia (5%). The most common nonhematologic TRAEs of Grade≥3 were pneumonia (14%) and upper respiratory tract infection (5%). Immune-mediated Grade≥3 TRAEs including elevated ALT, AST, diarrhea, colitis, rash were not reported or were <5%. Nine patients (9.2%) discontinued from the study due to various adverse events. The safety results of this study were consistent with previously reported data in other linperlisib clinical studies. About linperlisib Linperlisib, a next-generation PI3K-selective oral inhibitor, received marketing approval in China in 2022 for treatment of patients with relapsed and/or refractory follicular lymphoma after two or more systemic therapies. Linperlisib also received U.S. FDA Orphan Drug Designations for follicular lymphoma, chronic lymphocytic leukemia, and T cell lymphomas. Linperlisib is under investigation in multiple additional clinical trials as a monotherapy: frontline PTCL, r/r large granular T lymphocytic leukemia, r/r autoimmune hemolytic anemia; and in combination with other agents: in second line follicular lymphoma and marginal zone lymphoma, frontline PTCL, and r/r CTCL. In the U.S. and EU, linperlisib is being developed by 280Bio, Inc (San Francisco, CA., USA), a wholly-owned subsidiary of Yingli Pharma, in a Phase 2 clinical study in r/r T Cell Lymphomas [PTCL and CTCL]. About Yingli Pharma Shanghai Yingli Pharmaceutical Co., Ltd., founded in 2011 and located in the National Biomedical Industry Base of Shanghai Zhangjiang InnoPark, is a clinical-stage biotechnology company developing oral drugs for oncology and metabolic diseases. Yingli Pharma has partnered with Jiangsu Hengrui Pharmaceuticals Co., Ltd., for Greater China commercialization of linperlisib (Intarel®) in r/r follicular lymphoma that is conditionally approved, and other heme indications. Yingli Pharma is currently developing other oral agents in clinical stage from its oncology portfolio, including YL-13027 (TGFR1 inhibitor), YL17231 (pan-RAS inhibitor), YL-15293 (KRASG12C inhibitor), as well as a rich pipeline of additional novel oral agents in oncology. For more information, please see: SOURCE Shanghai Yingli Pharmaceutical Co., Ltd.

Phase 2Clinical ResultOrphan DrugASHDrug Approval

05 Sep 2022

·www.prnewswire.com

Yingli Pharma Announces First Patient Dosed in Phase 2 Trial of Linperlisib for Peripheral T Cell Lymphoma

SAN FRANCISCO, Sept. 3, 2022 /PRNewswire/ -- Yingli Pharma (the "Company" or "Yingli"), a clinical stage biotechnology company developing oral small molecule drugs for cancers with high unmet need, announced today that the first patient has been dosed in a Phase 2 trial evaluating linperlisib, a potent inhibitor of the delta isoform of PI3 kinase (PI3Kδ) in patients with relapsed/refractory peripheral T/NK cell lymphoma (r/r PTCL). This single arm study will evaluate the safety, efficacy and pharmacokinetics of orally administered linperlisib under a strategic collaboration with The University of Texas MD Anderson Cancer Center. Additional trial sites will include medical centers in the United States and Italy. "We are pleased to commence this study of linperlisib in the United States in patients suffering from advanced PTCL," said Michael Hui, MBA, chief executive officer of Yingli. "Linperlisib is a next generation inhibitor of PI3Kδ with enhanced selectivity and potency to offer strong anti-tumor effect while minimizing potential adverse reactions. We are encouraged by the safety and preliminary efficacy data obtained in Phase 1 dose-finding studies in China and look forward to further evaluating linperlisib's potential in this Phase 2 study." "Patients living with advanced PTCL, an aggressive type of lymphoma, face limited treatment options and most do not respond or stop responding to available therapies. Linperlisib may provide a solution for these patients who need an expanded treatment armamentarium, and we're excited to continue studying the drug's potential as we start the Phase 2 study." Linperlisib, a convenient once daily oral drug, is a small molecule inhibitor of PI3Kδ, a validated target in lymphomas due to its critical role in cell proliferation and survival. This Phase 2 (NCT05274997), single arm, open-label trial will evaluate the safety, efficacy and pharmacokinetic properties of linperlisib monotherapy in adult patients with r/r PTCL who have failed at least one prior line of systemic therapy. Enrolled participants will receive linperlisib 80mg once daily orally in a 28-day cycle. The primary outcome is overall response rate to treatment. Secondary outcomes include duration of response, overall survival, progression-free survival, adverse effects and pharmacokinetics parameters. An estimated 97 patients will be enrolled in the study. About Linperlisib Linperlisib (YY-20394) is a highly selective and potent PI3Kδ inhibitor that has shown a favorable safety profile, encouraging anti-tumor activities and promising PK and pharmaceutical properties as an oral once-a-day agent in late-stage clinical development. A Phase 1 clinical trial was completed in 2020 demonstrating linperlisib to be a safe and tolerable agent, and a recommended Phase 2 dose of 80 mg QD was established. Linperlisib was awarded NMPA Breakthrough Therapy status in China, leading to a Phase 2 study in follicular lymphoma (FL) that was completed and submitted in 2021 to China marketing authority for approval. In addition, linperlisib received FDA Orphan Drug Designations for FL, CLL/SLL and T cell lymphoma. Multiple linperlisib clinical trials in FL, PTCL, other lymphomas, solid tumors, combination with gemcitabine/oxaliplatin in r/r DLBC and combination with therapeutic PD1 antibody are underway in China. Preliminary results of single agent linperlisib from a relapsed or recurrent PTCL Phase1b study were reported at ASCO 2021, indicating an overall response rate of 70% with 33% CRs for this difficult to treat and aggressive form of lymphoma. About Yingli Pharma Yingli Pharma is developing oral small molecule drugs with first-in-class or best-in-class potential for cancers with high unmet need. In addition to linperlisib, Yingli's clinical stage portfolio under development in U.S. and China also includes YL-13027, a TGFbeta Receptor 1 small molecule antagonist, currently in Phase 1, and YL-15293, a KRAS G12C inhibitor in Phase 1 studies that are part of a precision medicine program targeting oncogene drivers in cancer. Yingli is advancing several early-stage precision therapy programs leading to IND-enabling studies this year. For more information, visit http://www.yl-pharma.com

CollaborateAntibodyOrphan DrugBreakthrough TherapyFirst in Class

26 May 2022

·www.globenewswire.com

Yingli Pharma Doses First US Patient in Phase 1 Study of YL-13027 for Patients with Advanced Solid Tumors

Phase 1 study evaluates safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YL-13027, an inhibitor of TGFβ signalingSAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- Yingli Pharma US, Inc, (the “Company” or “Yingli”), a clinical stage biotechnology company developing oral small molecule drugs for cancers and other diseases with high unmet need, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating YL-13027, a potent and selective TGFβ receptor 1 (TGFβR1) inhibitor. The dose-finding exploratory trial in patients with advanced solid tumors is being conducted in collaboration with The University of Texas MD Anderson Cancer Center and 4 clinical centers in the U.S. YL-13027 is an oral inhibitor designed to neutralize TGFβ signaling and enhance immunomodulation in the tumor microenvironment by selectively targeting TGFβR1. The Phase 1 study is evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YL-13027. The dose escalation portion of the study will include up to four cohorts of 3-6 patients who will be treated in 28-day cycles with YL-13027, and it will evaluate the safety and tolerability of the drug to determine the recommended Phase 2 dose. A dose expansion phase is planned to further evaluate the safety, tolerability and anti-tumor activity of the TGFβR1 inhibitor at the recommended Phase 2 dose. The study has an estimated enrollment of 54 participants. “The TGFβ pathway represents a promising target for cancer therapeutics. As yet, no therapies have been approved that inhibit TGFβR1 signaling,” said Michael Hui, MBA, chief executive officer of Yingli. “We are delighted to be opening the clinical study in the U.S. and hope to build on the positive preliminary results seen in the ongoing YL-13027 Phase 1 trial in China with promising pharmacokinetics, safety and preliminary evidence of durable antitumor activity. We believe that our drug has potential as a monotherapy or in combination with immunotherapies, and we’re excited to advance this therapy and provide patients with advanced solid tumors a convenient oral treatment option.” The Phase 1 study is part of an ongoing collaborative agreement between Yingli and MD Anderson. About YL-13027 YL-13027 is a potent and selective oral TGFβR1 inhibitor that is rationally designed to neutralize the TGFβ pathway and enhance immunomodulation in the tumor microenvironment. In IND-enabling studies, YL-13027 showed reliable dose-proportionality and pharmacokinetic properties and was safe and tolerable in toxicity studies. Preliminary results of a Phase 1 dose escalation clinical trial demonstrated that YL-13027 is safe, effective and well-tolerated. Yingli Pharma is also launching a Phase 1b/2 study in China exploring the benefits of YL-13027 in combination with a checkpoint inhibitor. About Yingli Pharma US, Inc.Yingli Pharma US, Inc. is developing oral small molecule drugs with first-in-class or best-in-class potential for cancers and other diseases with high unmet need. Its lead clinical candidate, linperlisib, is a next-generation PI3 kinase delta (PI3kδ) inhibitor under review in China for marketing approval in follicular lymphoma. Linperlisib is also under evaluation in a U.S. Phase 2 study in relapsed and refractory peripheral T cell lymphoma. Yingli’s clinical stage portfolio also includes YL-15293, a KRAS G12C inhibitor that is a part of its precision medicine program targeting oncogene drivers in cancer, under development in U.S. and China. In addition, Yingli is advancing several early-stage precision therapy programs leading to IND-enabling studies this year. For more information, visit http://www.yl-pharma.com Yingli Contact:Tes (Marites) Sotto Yingli Pharma US, Inctsotto@yl-pharma.com+1 650-410-5000 Media Contact:Veronica Eames LifeSci Communicationsveames@lifescicomms.com+1 646-970-4682

CollaborateFirst in ClassSmall molecular drug

100 Deals associated with Linperlisib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Recurrent Follicular Lymphoma	China	Shanghai Yingli Pharmaceutical Co., Ltd.	08 Nov 2022
Refractory Follicular Lymphoma	China	Shanghai Yingli Pharmaceutical Co., Ltd.	08 Nov 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peripheral T-Cell Lymphoma	NDA/BLA	China	Jiangsu Xuantai Pharmaceutical Co., Ltd	07 Sep 2023
Peripheral T-Cell Lymphoma	NDA/BLA	China	Shanghai Yingli Pharmaceutical Co., Ltd.	07 Sep 2023
Extranodal NK-T-Cell Lymphoma	Phase 2	United States	Shanghai Yingli Pharmaceutical Co., Ltd.	01 May 2022
thymic carcinoma	Phase 2	China	Shanghai Yingli Pharmaceutical Co., Ltd.	28 Jul 2021
NK-cell lymphoma	Phase 2	China	Shanghai Yingli Pharmaceutical Co., Ltd.	12 Mar 2021
Refractory Follicular Lymphoma	Phase 2	-	Shanghai Yingli Pharmaceutical Co., Ltd.	30 Dec 2020
Diffuse large B-cell lymphoma recurrent	Phase 2	-	Shanghai Yingli Pharmaceutical Co., Ltd.	20 Aug 2020
B-Cell Lymphoma	Phase 2	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	-
Recurrent Indolent Non-Hodgkin Lymphoma	Phase 2	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	-
Refractory Indolent Non-Hodgkin Lymphoma	Phase 2	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04500561 (Pubmed \| Cancer Cell Int) Manual	Phase 1/2	Diffuse Large B-Cell Lymphoma	39	Linperlisib + Gemcitabine + Oxaliplatin	(ankuoqvxmg) = eprrtvgvtg kumhpwenkb (smfwdxfkoe, 37.2 - 69.9) View more	Positive	08 Feb 2025
NCT04370405 (ASH2023)	Phase 2	Refractory Follicular Lymphoma	84	Linperlisib	(lmurqtrhgi) = owsgamqewe xfqupfudxr (bxdvkeijco ) View more	-	09 Dec 2023
ASH2023	Phase 1	B-Cell Malignant Neoplasm	43	Linperlisib	(htvtwvxaaa) = ihltwapukr zrvspyppao (qdxuudjqme, 31.2 - 62.3) View more	-	09 Dec 2023
ASH2023	Phase 2	Extranodal NK-T-Cell Lymphoma	98	Linperlisib 80 mg	tpavrhqtxb(yibzzzuwzc) = xjeifmiflm opzhswaucm (xttpajxgqz ) View more	Positive	09 Dec 2023
NCT04500561 (ASH2023)	Phase 1/2	Diffuse large B-cell lymphoma recurrent	39	Linperlisib + GEMOX	(fkgauukjpp) = nhbunmegdi hltshogwxu (twleejvlgq, 37.2 - 69.9) View more	-	09 Dec 2023
NCT04370405 (phase 2 trial, ICML2023)	Phase 2	Follicular Lymphoma	84	Linperlisib 80 mg	(zfauvzbdrv) = lnsanpmfjq yzfblkexlb (jsssgcvqda, 64.5 - 86.9) View more	Positive	09 Jun 2023
NCT04370405 (phase 2 trial, ICML2023)	Phase 2	Follicular Lymphoma	84	Placebo	(zfauvzbdrv) = hwkqxjktlm yzfblkexlb (jsssgcvqda, 66.4 - 97.2) View more	Positive	09 Jun 2023
NCT04370405 (EHA2023)	Phase 2	Follicular Lymphoma	84	LINPERLISIB (Relapsed-only disease)	(scjvhnozry) = bzigljlghn jvvwxpgioz (fxhxvrrfyj )	-	08 Jun 2023
NCT04370405 (EHA2023)	Phase 2	Follicular Lymphoma	84	LINPERLISIB (Refractory disease)	(scjvhnozry) = yzsdtennqj jvvwxpgioz (fxhxvrrfyj )	-	08 Jun 2023
NCT04370405 (EHA2023)	Phase 2	Follicular Lymphoma	84	Linperlisib 80 mg	(nmczcnmwit) = nnolreszpq bnfpwnjfpt (keankkunbo, 47.6 - 92.7) View more	-	08 Jun 2023
NCT04500561 (YY-20394-008, EHA2023)	Phase 2	Diffuse large B-cell lymphoma refractory \| Diffuse large B-cell lymphoma recurrent	39	Linperlisib + GEMOX	(fajgpjpdqe) = ctchubpzsh womfvidios (tfcyrbpiza, (40.0 - 97.2)) View more	-	08 Jun 2023
NCT04108325 (ASH 12022 \| ASH 22022) Manual	Phase 1	T-cell lymphoma recurrent	43	Linperlisib	(khtctbefyo) = pstkdfieiz hiqlcqkehh (voilsxxops ) View more	Positive	15 Nov 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Linperlisib

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation